An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Phase 3 results suggest intravenous vedolizumab is effective and safe for clinical remission in pediatric patients with moderate to severe UC.

As a part of this development strategy, Curanex will continue to advance its botanical drug development program in a stepwise ...

Crohn’s and UC affect the GI tract differently. Crohn’s impacts the whole tract, while UC is limited to the colon. Learn the ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for duvakitug in ulcerative colitis and Crohn's disease. The investigational monoclonal ...

ON THIS PAGESymptomsComplicationsWhy Fulminant Colitis OccursWhat to Do During a Severe UC FlareAfter a Fulminant UC EpisodeFor some people with ulcerative colitis (UC), the symptoms are mild. But for ...

Add Yahoo as a preferred source to see more of our stories on Google. “Debilitating digestive issues dominated my life because I couldn’t go longer than a half hour without going to the bathroom,” ...